From GlobeNewswire.

1. Tesla’s stock price soared to a record high of $2,213.40 per share, making the company the most valuable automaker in the world with a market capitalization of over $400 billion. This surge comes as Tesla continues to deliver strong sales numbers and expand its production capacity.

2. The latest jobs report revealed that the US economy added 1.76 million jobs in July, exceeding expectations and marking a slowdown in the unemployment rate to 10.2%. While this is a positive sign of recovery, economists warn that the pace of job growth may slow down in the coming months.

3. Apple announced a 4-for-1 stock split, which will make its shares more accessible to retail investors. The company’s stock has been performing well, reaching an all-time high of $464.68 per share. The split will take effect at the end of August, with shareholders receiving three additional shares for each share held.: 2025-05-06 08:00:00

Vera Therapeutics is set to announce primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy in 2Q 2025. The company plans to submit a Biologics License Application (BLA) for atacicept to the U.S. FDA in 4Q 2025 for accelerated approval. Vera also expanded its atacicept development program to include other autoimmune kidney diseases. The company reported a net loss of $51.7 million for the first quarter of 2025. Vera Therapeutics aims to advance treatments for serious immunological diseases, with a focus on atacicept, a fusion protein targeting B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL). The Phase 2b ORIGIN clinical trial of atacicept in IgAN showed promising results, with reductions in proteinuria and stabilization of eGFR. Atacicept has received FDA Breakthrough Therapy Designation for the treatment of IgAN, positioning it as a potential best-in-class therapy. Vera Therapeutics is also developing MAU868, a monoclonal antibody to neutralize BK virus infection, and holds an exclusive license for VT-109, a fusion protein with wide therapeutic potential. Vera Therapeutics, Inc. plans to receive and report primary endpoint results in the Phase 3 ORIGIN 3 trial, submit a BLA to the FDA, and potentially receive FDA approval for atacicept in IgAN. Financially, the company reported a net loss of $51,694 for the first quarter of 2025, with total assets amounting to $610,167.



Read more at GlobeNewswire.

1. Tesla’s stock price soared to a record high of $2,213.40 per share, making the company the most valuable automaker in the world with a market capitalization of over $400 billion. This surge comes as Tesla continues to deliver strong sales numbers and expand its production capacity.

2. The latest jobs report revealed that the US economy added 1.76 million jobs in July, exceeding expectations and marking a slowdown in the unemployment rate to 10.2%. While this is a positive sign of recovery, economists warn that the pace of job growth may slow down in the coming months.

3. Apple announced a 4-for-1 stock split, which will make its shares more accessible to retail investors. The company’s stock has been performing well, reaching an all-time high of $464.68 per share. The split will take effect at the end of August, with shareholders receiving three additional shares for each share held.:: Vera Therapeutics Provides Business Update and Reports